An interventional study of Denosumab and Teriparatide in Osteoporotic Fractures, sponsored by Peking Union Medical College Hospital. Recruiting at 58 sites in China. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Osteoporotic Fractures with a site in China — 7 open to participants now, 8 under way, none of them phase 3. Osteoporotic Fractures · China.
Among the 13 studies in Osteoporotic Fractures with a site in China, this one is one of 2 that started in 2023, is one of 5 with no phase, and was the 9th registered.
87 studies on the registry are indexed under Osteoporotic Fractures; 22 are open to participants now.
Browse Osteoporotic Fractures studies →7 of the 13 studies in Osteoporotic Fractures with a site in China are open now. Recruiting first, the newest first:
The Seventh Affiliated Hospital of Sun Yat-sen University · Sites in China
Ages 50–90
He Qifei · Sites in China
Ages 65+
Suzhou Municipal Hospital · Sites in China
Ages 65+ · Healthy volunteers
Peking University Third Hospital · Sites in China
Ages 50–100
Jiawei Jiang · Sites in China
Ages 58–84
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 14 Osteoporotic Fractures studies recruiting now, 9 (64%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 45 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,478 is above the median of 120 across 49 interventional studies indexed under Osteoporotic Fractures.
Median enrollment 321 across the 8 interventional studies, 500 across the 5 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 10 most frequent:
Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Peking Union Medical College Hospital has 3 studies filed under Osteoporotic Fractures — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoporotic Fractures with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07165158The First Affiliated Hospital of Xiamen UniversityThe Effect of Semaglutide on Bone Health | 2026-12-31 |
| NCT06379243The Seventh Affiliated Hospital of Sun Yat-sen UniversityDevelopment and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures | 2026-12-31 |
| NCT07178327Shanghai TTM-Bio Technology Co., LtdPhase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101 | 2027-03-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Osteoporotic Fractures with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This project anchors osteoporotic fractures, conduct registration and follow-up studies, and conduct prospective treatment studies. By registering for follow-up studies on osteoporotic fractures, it is planned to obtain epidemiological data through registration and follow-up studies; A prospective treatment study for patients with osteoporotic fractures is planned to explore effective treatment strategies through randomized controlled trials; To study biomarkers for osteoporotic refractures, we plan to establish a biomarker warning model through multi omics research; To study imaging biomarkers for osteoporotic refractures, a new imaging technology is proposed to establish an imaging omics warning model.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Monotherapy with denosumab injection ( 60mg, subcutaneous injection, semi-annually) for 24 months.
Drug: Denosumab
1. Treatment with teriparatide injection ( 20ug, subcutaneous injection, once daily) for 6 months, followed by discontinuation of teriparatide and change to denosumab injection ( 60mg, subcutaneous injection, once every six months) and continued until the 24th month. 2. Treatment with teriparatide injection ( 20ug, subcutaneous injection, once daily) for 12 months, followed by discontinuation of teriparatide and change to denosumab injection ( 60mg, subcutaneous injection, semi-annually) treatment continued until the 24th month.
Drug: Denosumab · Drug: Teriparatide
Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
Teriparatide was sequentially treated with Denosumab
The main study:The incidence of new vertebral fractures
The main study:the incidence of new vertebral fractures (clinical and imaging) within 24 months of treatment
Time frame: Within 24 months of treatment
The sub study:The rate of change in BMD from baseline at lumbar spine in 24 months
Time frame: Within 24 months of treatment
The main study:New vertebral fractures in 12 months
Time frame: Within 12 months of treatment
The main study:New hip fractures, new fractures at other sites, and all new fractures at 12 and 24 months
Time frame: Within 12 months and 24 months of treatment
The main study:The rate of BMD change from the baseline at the lumbar spine, total hip, and femoral neck in 12 and 24 months;
Time frame: Within 12 months and 24 months of treatment
The main study:The rate of changes from baseline in serum type 1 collagen cross-linked C-terminal peptide (β-CTX) and type 1 procollagen N-terminal propeptide (P1NP) at 6, 12, and 24 months
Time frame: 6, 12, and 24 months
The main study:The patients' adherence to treatment
Non-adherence rate=Number of patients non-adherencet with teriparatide or denosumab / Total number of patients. 1. Denosumab Adherence Adherence to denosumab treatment was assessed based on protocol compliance during the study period. Non-adherence was defined as one or more instances in which the scheduled denosumab injection was not administered according to the study protocol, including doses received outside the permissible treatment window (±4 weeks). 2. Teriparatide Adherence Adherence to teriparatide was evaluated only in the two sequential treatment groups assigned to receive teriparatide. Using patient diary records, non-adherence was defined as an actual-to-expected injection day ratio of less than 80% or greater than 120% over the course of the study period.
Time frame: 24 months
The main study:Cost-effectiveness
The incremental cost-effectiveness ratio is defined as the average additional drug cost required per additional fracture event avoided in the intervention group compared to the control group.
Time frame: 24 months
The sub study:BMD change at lumbar spine in 12 months
Time frame: Within 12 months of treatment
The sub study:BMD changes at total hip and femoral neck in 12 and 24 months
Time frame: Within 12 months and 24 months of treatment
The sub study:Serum β-CTX and P1NP levels at 12 and 24 months
Time frame: 12 months and 24 months
The sub study:The incidence of new vertebral fractures, hip fractures, new fractures at other sites, and all new fractures in 12 and 24 months
Time frame: Within 12 months and 24 months of treatment
Plan to share: Yes — Data related to this study will be made available upon reasonable request.
Supporting information: Study protocol
Started May 2023 (actual). Primary completion is estimated for Sep 2026, 40 months after the start.
Of 22 interventional studies with no phase under Osteoporotic Fractures, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 60. This study's planned 40 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teriparatide
Peking Union Medical College Hospital →